Avoro Ventures
VC Fund
Avoro Ventures is an investment firm that manages biopharma venture funds.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Avoro Ventures invests in
Stages Avoro Ventures invests in
Countries Avoro Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 5 (71%)
- Medical 3 (43%)
- Life Science 3 (43%)
- Biopharma 1 (14%)
- Health Care 1 (14%)
Stage
- Series B 4 (57%)
- Series C 1 (14%)
- Post-IPO Equity 1 (14%)
Country
- United States 3 (43%)
- Denmark 1 (14%)
- United Kingdom 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Behzad Aghazadeh
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hemab
|
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $157M / Series C / Oct 27, 2025 | |
Vicebio
|
Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses. Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections. | $100M / Series B / Sep 23, 2024 | |
|
Hemab
|
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $135M / Series B / Feb 21, 2023 | |
Vanqua Bio
|
Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases. Founded in 2019, the company's technology platform utilizes human genetics and patient-derived neuronal cells to identify, validate, and clinically translate novel disease pathways associated with lysosomaldysfunction or aberrant activation of the innate immune system. | $85M / Series B / Sep 14, 2021 | |
|
Vanqua Bio
|
Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases. Founded in 2019, the company's technology platform utilizes human genetics and patient-derived neuronal cells to identify, validate, and clinically translate novel disease pathways associated with lysosomaldysfunction or aberrant activation of the innate immune system. | $85M / Series B / Sep 14, 2021 | |
Whitehawk Therapeutics
|
Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $155M / Post-IPO Equity / Aug 26, 2021 | |
Scribe Therapeutics
|
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. Italso a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives.Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting.Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA. | $100M / Series B / Mar 31, 2021 |
Co-Investors
OrbiMed
9 deals together
Omega Funds
4 deals together
Access Biotechnology
3 deals together
Avoro Capital Advisors
3 deals together
RA Capital Management
3 deals together
Rock Springs Capital
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Avoro Ventures invest in?
Avoro Ventures invests primarily in Biotechnology, Medical and Life Science startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Avoro Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Avoro Ventures?
The team at Avoro Ventures includes Behzad Aghazadeh (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
